Conversely, for advanced colorectal cancer patients with the BRAF-V6000E mutation, where the therapeutic standard is an association of a RAF inhibitor plus an EGFR inhibitor [15], there is the beneficial possibility to escalate treatment with the addition of an MEK inhibitor when the plasmatic BRAF-V6000E allele fraction is high [16]. This evidence concerns the gene BRAF and colorectal cancer.